title: Interfering with inflammation: a new strategy to block breast cancer self-renewal and progression?
abstract: Two recent studies show that epigenetics and inflammation play a relevant role in the regulation of transformation and cancer cell self-renewal in breast tumours, opening up the possibility that cancer progression can be controlled by interfering with inflammation cascades. Struhl's group showed that transient activation of the Src oncoprotein induces transformation and self-renewal of immortal cells via an epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA and IL-6. Concomitantly, Wicha's laboratory developed a strategy to selectively target cancer stem cells, retarding tumour growth and reducing metastasis by blocking the IL-8 receptor CXCR1 using either an inhibitor, repertaxin or a specific blocking antibody.
authors.affiliation: Dept. of Oncological Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza 52, Turin, Italy. sara.cabodi@unito.it
authors.forename: Sara
authors.initials: S
authors.lastname: Cabodi
authors.forename: Daniela
authors.initials: D
authors.lastname: Taverna
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D019138:Antibodies, Blocking / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D002460:Cell Line; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics / Q000473:pathology*; D018450:Disease Progression; D044127:Epigenesis, Genetic; D005812:Genes, Switch / Q000235:genetics; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D015850:Interleukin-6 / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000473:pathology*; D015688:Oncogene Protein pp60(v-src) / Q000378:metabolism; D023062:Receptors, Interleukin-8A / Q000037:antagonists & inhibitors / Q000276:immunology; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D019138:Antibodies, Blocking; D000970:Antineoplastic Agents; D015850:Interleukin-6; D023062:Receptors, Interleukin-8A; D013449:Sulfonamides; D015688:Oncogene Protein pp60(v-src); C490707:reparixin
references.citation: J Clin Oncol. 2009 Jul 20;27(21):3437-44
references.pmid: 19470939
references.citation: Cell. 2007 Dec 14;131(6):1109-23
references.pmid: 18083101
references.citation: Cell. 2009 Nov 13;139(4):693-706
references.pmid: 19878981
references.citation: Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11
references.pmid: 16341240
references.citation: J Clin Invest. 2010 Feb;120(2):485-97
references.pmid: 20051626
references.citation: N Engl J Med. 2002 Nov 14;347(20):1593-603
references.pmid: 12432047
references.citation: Nat Rev Cancer. 2008 Oct;8(10):755-68
references.pmid: 18784658
references.citation: Clin Cancer Res. 2009 Jun 15;15(12):4234-41
references.pmid: 19509181
references.citation: Cell. 2009 Jan 23;136(2):215-33
references.pmid: 19167326
references.citation: Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6
references.pmid: 15282370
references.citation: J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85
references.pmid: 17179479